Copyright
©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 5934-5945
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.5934
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.5934
CRISPR type | Specific cleavage | Collateral cleavage | Secondary messenger | CRISPR inhibitors | Ref. | |
Class 1 | I (Cas8) | DNA | Not identified to date | Not identified to date | Yes | [4] |
III (Cas10) | RNA | RNA, ssDNA | cOA | Not identified to date | [6-8] | |
IV (Csf1) | Not studied yet | Not studied yet | Not studied yet | Not studied yet | [16] | |
Class 2 | II (Cas9) | DNA | Not identified to date | Not identified to date | Yes | [4,5,16-20] |
V (Cas12, Cas14) | DNA | ssDNA | Not identified to date | Yes | [21-23] | |
VI (Cas13) | RNA | RNA | Not identified to date | Not identified to date | [24-26] |
- Citation: Huang YY, Zhang XY, Zhu P, Ji L. Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications. World J Clin Cases 2022; 10(18): 5934-5945
- URL: https://www.wjgnet.com/2307-8960/full/v10/i18/5934.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.5934